Sanofi and CD&R partner to fuel Opella’s ambitions in consumer healthcare Sanofi and CD&R enter exclusive negotiations to transfer a 50% controlling stake in Opella with Sanofi to remain ...

Sanofi in discussions to sell a controlling stake in Opella Paris, . Sanofi today announces that the company has entered into negotiations with CD&R for the potential sale of ...

Sanofi and Orano join forces to develop next-generation radioligand medicines Paris, . Sanofi and Orano Med, a subsidiary of the Orano Group and a pioneer in the development ...

We want to improve the lives of millions of people who don’t have access to the help they need. To do that, we’re expanding our health-system partnerships at local, regional, and global levels.

We want to build a healthier, more resilient world. We turn the impossible into the possible by discovering, developing, and delivering medicines and vaccines for millions of people around the world.

Third quarter 2024 results will be reviewed by management during a live audio webcast with the financial community. The presentation will be followed by a Q&A session. We’re proud to be premium ...

We’re using AI to chase the miracles of science by accelerating drug discovery, enhancing clinical trial design, and improving the manufacturing and supply of medicines and vaccines to get them to ...

Paul Hudson is reshaping Sanofi into a modern healthcare company with the ambition to transform the practice of medicine. Paul and the Sanofi teams are focusing efforts to discover, develop, ...

The www.sanofi.com website (hereinafter the “site”) is owned and operated by SANOFI WINTHROP INDUSTRIE, belonging to Groupe Sanofi. The presentation and each of the elements, including trademarks, ...

Our incredibly talented, creative scientists dig into a rich toolbox of technologies to develop smart, safe, effective medicines and vaccines that break the mold. Our integrated genomic medicine unit ...